

**MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING OF RE-TENDER
BMSIC/DRUGS/19-03 (RATE CONTRACT AND SUPPLY OF DRUGS FOR DIFFERENT
HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 14th June 2019

Venue: BMSICL Conference Hall.

The Financial Evaluation Committee meeting for evaluation of financial bids of Tender No. BMSIC/DRUGS/19-03 was held on 14th June 2019 under the Chairmanship of Managing Director, BMSICL. The other committee members present in the meeting were:

1. Dr. R D Ranjan, Director in Chief, Health Dept., GoB.
2. Sh. Khalid Arshad, AO, State Health Society.
3. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
4. Dr. Ramji Prasad, Principal PMCH, Patna.
5. Sh. Sheo Nandan Prasad; Assistant Internal Financial Advisor (IFA) of Health Dept., GoB (For IFA).
6. Sh. Sunil Kumar Singh, GM (Procurement), BMSICL.
7. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/19-03.
2. Tender floated date- 28/01/2019
3. Last date of submission of Online bids- 03/04/2019
4. Tender Opening date- 08/04/2019.

3. Tender has been floated for 9 (Nine) drugs. It was found in online opening that the following 2 (Two) bidders had participated in the tender:


1. Baxalta Bioscience India Pvt. Ltd.
2. Hemarus Therapeutics Ltd.

4. The summary of bid received status were as follows:

1. No Bid received for 8 Drugs.
2. Multiple Bids received for 1 Drug.

5. It was unanimously decided in Tender Opening Committee meeting dated 08.04.19 to proceed further for preliminary technical evaluation of both the received bids for NIT S. No. 1 (Human Coagulation Factor IX) for which multiple bids were received, by the team of Drug Inspectors deputed at BMSICL and re-tender for the remaining 8 Drugs (NIT S. No. 2,3,4,5,6,7,8 & 9) due to no bid condition.

6. The Preliminary Evaluation of technical bids of the above mentioned bidding firms were done by the team of Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections/clarification were invited vide notice no. 602 dated 09.05.2019.



7. After comparison of the clarification received from the bidders in the light of that notice and close examination of the documents submitted by the bidders, the drug wise technical evaluation findings were recorded by the TEC in its meeting dated 28.05.2019 as follows:

S. N	Name of the Drugs with Specification	Participating Firms	Remarks of the TEC
1	Human Coagulation Factor IX (Dried powder for Injection 600IU)	Baxalta Bioscience India Pvt. Ltd	Technically Qualified
		Hemarus Therapeutics Ltd.	Technically Qualified

As M/s Baxalta Bioscience India Pvt. Ltd was one importer firm and M/s Hemarus Therapeutics Ltd. was one manufacturer. It was also recommended in that TEC meeting to carry out the inspection of the manufacturing unit of M/s Hemarus Therapeutics Ltd.

8. In accordance with the decision taken by the committee in its meeting dated 28.05.2019, the factory inspection of the firm M/s Hemarus Therapeutics Ltd. was conducted by the team of Drug Inspectors deputed for this purpose.


Accordingly, the factory inspection report was placed before the committee in its last meeting dated 12.06.2019. After perusal of which, the technical evaluation finding for the below mentioned drug were recorded as follows:

S. N	Name of the Drugs with Specification	Participating Firms	Recommendation of the TEC before Factory Inspection (Qualified/ Disqualified)	Recommendation of TEC after factory inspection (Qualified/ Disqualified)
1	Human Coagulation Factor IX (Dried powder for Injection 600IU)	Baxalta Bioscience India Pvt. Ltd	Technically Qualified	Technically Qualified
		Hemarus Therapeutics Ltd.	Technically Qualified	Technically Qualified

9. It was unanimously decided in that meeting to recommend for opening of the financial bids of the above mentioned qualified firms for the above mentioned drug.

Accordingly, in today's meeting financial bids of both the firms i.e. M/s Baxalta Bioscience India Pvt. Ltd & M/s Hemarus Therapeutics Ltd. were opened online on E-Proc.

10. After opening of the financial bids (downloaded copies annexed as Annexure I) the rates quoted by both the technically qualified bidders were found as following and after comparison of which the bid ranking status is recorded as below: -



S. N	Name of the Drugs with Specification	Participating Firms	Rate as Per Financial Bid	Bid Ranking
			Rate Per unit excluding GST	
1	Human Coagulation Factor IX (Dried powder for Injection 600IU)	Baxalta Bioscience India Pvt. Ltd	8460 /-	L2
		Hemarus Therapeutics Ltd.	7775 /-	L1

11. It was therefore decided unanimously to issue Lol to the L1 Bidder i.e., **Hemarus Therapeutics Ltd** for the above-mentioned Product.

12. The meeting was thus concluded with a vote of thanks.

Sd/-
(Ramendra Kumar)
 GM (Finance) BMSICL, Patna.

Sd/-
(Sunil Kumar Singh)
 GM (Procurement) BMSICL, Patna.

Sd/-
(Sheo Nandan Prasad)
 AIFA, Health Dept. Govt. of Bihar

Sd/-
(Dr. Ramji Prasad)
 Principal, PMCH, Patna.

Sd/-
(Rajani Kant)
 CGM (Supply Chain), BMSICL, Patna

Sd/-
(Khalid Arshad)
 Administrative Officer, SHSB.

Sd/-
(Dr. R.D. Ranjan)
 Director in Chief, Health Dept.
 Govt. of Bihar.

Sd/-
(Sanjaya Kumar Singh)
 Managing Director, BMSICL

